首頁 > 市場調查報告書 > 製藥

孤兒藥

市場調查報告書

商品編碼

1983233

尼曼匹克病C型（NPC）治療市場：依藥物類型、適應症、通路及地區分類

Niemann-Pick Disease Drug Type C Treatment Market, By Drug Type, By Indication, By Distribution Channel, By Geography

出版日期: 2026年02月26日 | 出版商:

Coherent Market Insights | 英文 168 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，尼曼匹克病 C 型 (NPC) 治療市場規模將達到 1.009 億美元，到 2033 年將達到 4.06 億美元。預計從 2026 年到 2033 年，該市場將以 22% 的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	1.09億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	22.00%	2033年市場規模預測：	4.06億美元

尼曼-匹克病C型（NPC）是一種罕見的遺傳性疾病。這種基因突變會導致膽固醇和其他脂質在肝臟、脾臟或肺部積聚，也會影響大腦。 NPC的症狀出現時間隨年齡而異，分為嬰兒期（出生至6歲以下）、青少年期（6至15歲）及成年期（15歲以上）。在嬰兒期，NPC可導致α1-抗胰蛋白酶缺乏症、酪胺酸血症、高雪氏症、特發性新生兒膽汁淤積症以及各種性行為感染等疾病。

市場動態

預計在預測期內，各國政府加大對罕見疾病的投入將推動全球尼曼-匹克病C型（NPC）治療市場的成長。例如，2021年11月，義大利參議院一致通過了一項關於罕見疾病的統一法案。該法案旨在統一義大利全國的罕見疾病治療標準，並加快相關研究的進展。此外，該法案還規定設立一個罕見疾病患者互助基金，初始累計為每年101萬美元，自2022年起生效。

預計在預測期內，市場相關人員之間合作與協議的增加將推動全球尼曼-匹克病C型（NPC）治療市場的成長。例如，2022年5月，專業製藥公司Kempharm, Inc.宣布與全球生物製藥公司ORPHAZYME A/S達成協議，收購arimochromol，這是一種口服的、First-in-Class的熱休克蛋白（HSP）擴增劑，目前正在開發用於治療尼曼-匹克病C型（NPC）。

預計市場參與企業研發活動的活性化將推動預測期內的市場成長。例如，2021年6月，臨床階段生物技術公司Cyclo Therapeutics, Inc.宣布啟動一項III期主要臨床試驗（TransportNPC），以評估Trappsol Cyclo（一種專有的羥丙基BETA-環糊精製劑）治療NPC1的療效。 TransportNPC試驗是一項隨機、雙盲、安慰劑對照、平行組、多中心研究，旨在評估靜脈注射Trappsol Cyclo 2000 mg/kg聯合標準治療（SOC）與靜脈注射NPC1患者的安全性、耐受性和有效性。

本次考試的主要特點。

本報告以 2021 年為基準年，對全球尼曼匹克病 C 型 (NPC) 治療市場進行了詳細分析，並預測了其在預測期 (2022-2030 年) 內的市場規模。
本報告指出了各個細分市場的潛在商機，並說明了該市場中具有吸引力的投資提案矩陣。
此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、區域前景以及主要企業採取的競爭策略的重要見解。
本報告根據以下參數對全球尼曼匹克病 C 型 (NPC) 治療市場的主要企業進行了分析：公司概況、財務業績、產品系列、地理分佈、分銷策略、關鍵發展和策略以及未來計劃。
透過利用本報告中提出的見解，企業行銷負責人和經營團隊可以就未來的產品發布、技術升級、市場擴張和行銷策略做出明智的決策。
本報告面向該行業的眾多相關人員，包括投資者、供應商、製造商、經銷商、新參與企業和金融分析師。
相關人員可以利用分析全球尼曼-匹克病 C 型 (NPC) 治療市場中使用的各種策略矩陣來促進決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 亞太其他地區
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 南非
- 中非
- 北非

第8章競爭情勢

公司簡介
- Johnson &Johnson
- Intrabio
- Cyclo Therapeutics, Inc.
- Kempharm, Inc
- Azafaros BV
- StrideBio
- Sarepta Therapeutics, Inc.

第9章

調查方法
分析師意見
關於本公司
詢問

簡介目錄

Product Code: CMI4275

Niemann-Pick Disease Drug Type C Treatment Market is estimated to be valued at USD 100.9 Mn in 2026 and is expected to reach USD 406.0 Mn by 2033, growing at a compound annual growth rate (CAGR) of 22% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 100.9 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	22.00%	2033 Value Projection:	USD 406.0 Mn

Niemann-Pick Type C (NPC) is a rare inherited disease. This type of genetic mutation causes cholesterol and other fats to build up in the liver, spleen, or lungs. It has an impact on the brain as well. The onset of symptoms for NPC may begin at different ages. It has been grouped as: infantile (after birth to less than 6 years), juvenile (6 to 15 years), and adults (15 years to greater). In infants, NPC leads to disorders such as alpha-1-antitrypsin deficiency, tyrosinemia, Gaucher disease, idiopathic neonatal cholestasis, and various congenital infections.

Market Dynamics

Increasing government initiatives for rare diseases is expected to foster global niemann-pick disease type C treatment market growth over the forecast Period. For instance, in November 2021, the Italian senate unanimously approved the consolidated act on rare diseases. The aim of the act is to make the treatment of rare diseases uniform throughout the Italian territory and to promote progress in research. Moreover, the act also provides for the establishment of solidarity fund for people with rare diseases, with an initial budget of US$ 1.01 million per year starting from 2022.

Rising numbers of collaborations and agreements by market players are expected to drive growth of the global Niemann-pick disease drug type C treatment market over the forecast period. For instance, in May 2022, Kempharm, Inc., a specialty pharmaceutical company, announced an agreement with ORPHAZYME A/S, a global biopharmaceutical company, to acquire arimoclomol, an orally-delivered, first-in-class heat shock protein (HSP) amplifier being developed as a treatment for Niemann-Pick disease type C (NPC)

Increasing research and development activities by market players are expected to drive growth of market over the forecast period. For instance, in June 2021, Cyclo Therapeutics, Inc., a clinical-stage biotechnology company, announced the commencement of its pivotal Phase 3 study (TransportNPC) for the evaluation of Trappsol Cyclo, a proprietary formulation of hydroxypropyl beta cyclodextrin, delivered intravenously, for treating Niemann-Pick Disease Type C1 (NPC1). The TransportNPC study is a randomized, double-blind, placebo-controlled, parallel group, multicenter study designed to evaluate the safety, tolerability, and efficacy of 2,000 mg/kg of Trappsol Cyclo administered intravenously and standard of care (SOC) compared to placebo administered intravenously and SOC in patients with NPC1.

Key features of the study

This report provides an in-depth analysis of the global Niemann-pick disease drug type C treatment market , market size (US$ Million), and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains an attractive investment proposition matrix for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global Niemann-pick disease drug type C treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
Key companies covered as a part of this study include Livewise Johnson & Johnson, Intrabio, Cyclo Therapeutics, Inc., Kempharm, Inc., Azafaros B.V., StrideBio. Sarepta Therapeutics, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make an informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics.
The global Niemann-pick disease drug type C treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global Niemann-pick disease drug type C treatment market

Market Segmentation

By Drug Type
- Phase III Drug
- Trappsol Cyclo
- IB1001
- Marketed Drug
- Miglustat (Zavesca)
By Indication
- Niemann-Pick Disease Drug Type C1
- Niemann-Pick Disease Drug Type C2
By Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
Global Niemann-Pick Disease Drug Type C Treatment Market - Competitive Landscape
- Johnson & Johnson
- Intrabio
- Cyclo Therapeutics, Inc.
- Kempharm, Inc.
- Azafaros B.V.
- StrideBio
- Sarepta Therapeutics, Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Porter's Analysis
Industry Trends
Pipeline Analysis
Key Highlights
Epidemiology
Reimbursement Scenario
Regulatory Scenario
Product Launch and Approvals
Acquisition and Collaboration Scenario

4. Global Niemann-Pick Disease Drug Type C Treatment Market, By Drug Type, 2026-2033 (US$ Million)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026-2033
- Segment Trends
Phase III Drug
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Million)
  - Trappsol Cyclo
  - IB1001
Marketed Drug
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Million)
  - Miglustat (Zavesca)

5. Global Niemann-Pick Disease Drug Type C Treatment Market, By Indication, 2026-2033 (US$ Million)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026-2033
- Segment Trends
Niemann-Pick Disease Drug Type C1
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Million)
Niemann-Pick Disease Drug Type C2
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Million)

6. Global Niemann-Pick Disease Drug Type C Treatment Market, By Distribution Channel, 2026-2033 (US$ Million)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026-2033
- Segment Trends
Hospitals Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Million)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Million)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Million)

7. Global Niemann-Pick Disease Drug Type C Treatment Market, By Region, 2026-2033 (US$ Million)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2026-2033
- Regional Trends
North America
- Market Size and Forecast, By Drug Type, 2026-2033 (US$ Mn)
- Market Size and Forecast, By Indication, 2026-2033 (US$ Mn)
- Market Size and Forecast, By Distribution Channels, 2026-2033 (US$ Mn)
- Market Size and Forecast, By Country, 2026-2033 (US$ Mn)
  - U.S.
  - Canada
Latin America
- Market Size and Forecast, By Drug Type, 2026-2033 (US$ Mn)
- Market Size and Forecast, By Indication, 2026-2033 (US$ Mn)
- Market Size and Forecast, By Distribution Channels, 2026-2033 (US$ Mn)
- Market Size and Forecast, By Country, 2026-2033 (US$ Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Market Size and Forecast, By Drug Type, 2026-2033 (US$ Mn)
- Market Size and Forecast, By Indication, 2026-2033 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033 (US$ Mn)
- Market Size and Forecast, By Country, 2026-2033 (US$ Mn)
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Size and Forecast, By Drug Type, 2026-2033 (US$ Mn)
- Market Size and Forecast, By Indication, 2026-2033 (US$ Mn)
- Market Size and Forecast, By Distribution Channels, 2026-2033 (US$ Mn)
- Market Size and Forecast, By Country, 2026-2033 (US$ Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Market Size and Forecast, By Drug Type, 2026-2033 (US$ Mn)
- Market Size and Forecast, By Indication, 2026-2033 (US$ Mn)
- Market Size and Forecast, By Country, 2026-2033 (US$ Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Market Size and Forecast, By Drug Type, 2026-2033 (US$ Mn)
- Market Size and Forecast, By Indication, 2026-2033 (US$ Mn)
- Market Size and Forecast, By Distribution Channels, 2026-2033 (US$ Mn)
- Market Size and Forecast, By Country/Region, 2026-2033 (US$ Mn)
  - South Africa
  - Central Africa
  - North Africa

8. Competitive Landscape

Company Profiles
- Johnson & Johnson
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Intrabio
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Cyclo Therapeutics, Inc.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Kempharm, Inc
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Azafaros B.V
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- StrideBio
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies
- Sarepta Therapeutics, Inc.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Developments/Updates
  - Strategies

9. Section

Research Methodology
Analyst Views
About us
Contact

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

尼曼-匹克症C型藥物市場按藥物類別、給藥途徑和最終用戶分類，全球預測，2026-2032年

FAQ

尼曼匹克病C型（NPC）治療市場：依藥物類型、適應症、通路及地區分類

Niemann-Pick Disease Drug Type C Treatment Market, By Drug Type, By Indication, By Distribution Channel, By Geography

市場動態

目錄

第1章：研究目標與前提條件

第2章市場概覽

第3章：市場動態、監管與趨勢分析

第4章全球尼曼-匹克症C型（NPC）治療市場：依藥物類型分類，2026-2033年

第5章全球尼曼匹克症C型（NPC）治療市場：依適應症分類，2026-2033年

第6章全球尼曼-匹克病C型（NPC）治療市場：依通路分類，2026-2033年

第7章全球尼曼-匹克病C型（NPC）治療市場：依地區分類，2026-2033年

第8章競爭情勢

第9章

Market Dynamics

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Overview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Niemann-Pick Disease Drug Type C Treatment Market, By Drug Type, 2026-2033 (US$ Million)

5. Global Niemann-Pick Disease Drug Type C Treatment Market, By Indication, 2026-2033 (US$ Million)

6. Global Niemann-Pick Disease Drug Type C Treatment Market, By Distribution Channel, 2026-2033 (US$ Million)

7. Global Niemann-Pick Disease Drug Type C Treatment Market, By Region, 2026-2033 (US$ Million)

8. Competitive Landscape

9. Section

尼曼匹克病C型（NPC）治療市場：依藥物類型、適應症、通路及地區分類

Niemann-Pick Disease Drug Type C Treatment Market, By Drug Type, By Indication, By Distribution Channel, By Geography

市場動態

目錄

第1章：研究目標與前提條件

第2章 市場概覽

第3章：市場動態、監管與趨勢分析

第4章 全球尼曼-匹克症C型（NPC）治療市場：依藥物類型分類，2026-2033年

第5章 全球尼曼匹克症C型（NPC）治療市場：依適應症分類，2026-2033年

第6章 全球尼曼-匹克病C型（NPC）治療市場：依通路分類，2026-2033年

第7章 全球尼曼-匹克病C型（NPC）治療市場：依地區分類，2026-2033年

第8章 競爭情勢

第9章

Market Dynamics

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Overview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Niemann-Pick Disease Drug Type C Treatment Market, By Drug Type, 2026-2033 (US$ Million)

5. Global Niemann-Pick Disease Drug Type C Treatment Market, By Indication, 2026-2033 (US$ Million)

6. Global Niemann-Pick Disease Drug Type C Treatment Market, By Distribution Channel, 2026-2033 (US$ Million)

7. Global Niemann-Pick Disease Drug Type C Treatment Market, By Region, 2026-2033 (US$ Million)

8. Competitive Landscape

9. Section

第2章市場概覽

第4章全球尼曼-匹克症C型（NPC）治療市場：依藥物類型分類，2026-2033年

第5章全球尼曼匹克症C型（NPC）治療市場：依適應症分類，2026-2033年

第6章全球尼曼-匹克病C型（NPC）治療市場：依通路分類，2026-2033年

第7章全球尼曼-匹克病C型（NPC）治療市場：依地區分類，2026-2033年

第8章競爭情勢